RaQualia Pharma Inc. (TYO:4579)

RaQualia Pharma Statistics

Total Valuation

RaQualia Pharma has a market cap or net worth of JPY 13.45 billion. The enterprise value is 13.03 billion.

Market Cap	13.45B
Enterprise Value	13.03B

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

RaQualia Pharma has 24.46 million shares outstanding. The number of shares has increased by 3.04% in one year.

Current Share Class	24.46M
Shares Outstanding	24.46M
Shares Change (YoY)	+3.04%
Shares Change (QoQ)	+9.78%
Owned by Insiders (%)	13.69%
Owned by Institutions (%)	-1.68%
Float	16.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.16
PB Ratio	2.14
P/TBV Ratio	5.41
P/FCF Ratio	n/a
P/OCF Ratio	200.77
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 56.88, with an EV/FCF ratio of -289.47.

EV / Earnings	-24.76
EV / Sales	4.03
EV / EBITDA	56.88
EV / EBIT	n/a
EV / FCF	-289.47

Financial Position

The company has a current ratio of 4.80, with a Debt / Equity ratio of 0.51.

Current Ratio	4.80
Quick Ratio	4.24
Debt / Equity	0.51
Debt / EBITDA	13.95
Debt / FCF	-71.00
Interest Coverage	-4.46

Financial Efficiency

Return on equity (ROE) is -8.82% and return on invested capital (ROIC) is -1.66%.

Return on Equity (ROE)	-8.82%
Return on Assets (ROA)	-1.56%
Return on Invested Capital (ROIC)	-1.66%
Return on Capital Employed (ROCE)	-2.80%
Revenue Per Employee	50.48M
Profits Per Employee	-8.22M
Employee Count	64
Asset Turnover	0.32
Inventory Turnover	4.56

Taxes

In the past 12 months, RaQualia Pharma has paid 150.00 million in taxes.

Income Tax	150.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.60% in the last 52 weeks. The beta is 0.75, so RaQualia Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-8.60%
50-Day Moving Average	548.30
200-Day Moving Average	464.59
Relative Strength Index (RSI)	50.87
Average Volume (20 Days)	312,560

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RaQualia Pharma had revenue of JPY 3.23 billion and -526.00 million in losses. Loss per share was -23.61.

Revenue	3.23B
Gross Profit	2.44B
Operating Income	-250.00M
Pretax Income	-376.00M
Net Income	-526.00M
EBITDA	229.00M
EBIT	-250.00M
Loss Per Share	-23.61

Balance Sheet

The company has 3.62 billion in cash and 3.20 billion in debt, giving a net cash position of 427.00 million or 17.46 per share.

Cash & Cash Equivalents	3.62B
Total Debt	3.20B
Net Cash	427.00M
Net Cash Per Share	17.46
Equity (Book Value)	6.29B
Book Value Per Share	257.02
Working Capital	3.89B

Cash Flow

In the last 12 months, operating cash flow was 67.00 million and capital expenditures -112.00 million, giving a free cash flow of -45.00 million.

Operating Cash Flow	67.00M
Capital Expenditures	-112.00M
Free Cash Flow	-45.00M
FCF Per Share	-1.84

Margins

Gross margin is 75.64%, with operating and profit margins of -7.74% and -16.28%.

Gross Margin	75.64%
Operating Margin	-7.74%
Pretax Margin	-11.64%
Profit Margin	-16.28%
EBITDA Margin	7.09%
EBIT Margin	-7.74%
FCF Margin	n/a

Dividends & Yields

RaQualia Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.04%
Shareholder Yield	n/a
Earnings Yield	-3.91%
FCF Yield	-0.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RaQualia Pharma has an Altman Z-Score of 2.45 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.45
Piotroski F-Score	5